Dr. Reddy’s Russian Subsidiary Faces VAT Reclassification Penalty Deemed Immaterial
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dr Reddy’s Laboratories ( (RDY) ) has shared an announcement.
On January 23, 2026, Dr. Reddy’s Laboratories LLC, Russia, a step-down wholly owned subsidiary of Dr. Reddy’s Laboratories Limited, received a tax audit decision from the Interdistrict Inspectorate of the Federal Tax Service of Russia, which reclassified certain marketing services as taxable services subject to value added tax (VAT). The Russian tax authority has imposed a penalty of RUB 20.09 million (approximately INR 24.50 million), but Dr. Reddy’s has stated that, based on its evaluation, the matter is not expected to have a material impact on the group’s financials, operations or other activities, and the company plans to submit an appropriate reply to the authority.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven primarily by strong fundamentals (profitability, growth, and low leverage), tempered by weaker cash-flow conversion. Technical signals are neutral-to-soft with negative momentum versus longer-term averages, while valuation is reasonable but not especially cheap and the dividend is small. The latest earnings call was mixed due to U.S. generics weakness, margin pressure, and regulatory headwinds despite continued growth elsewhere.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company headquartered in Hyderabad, Telangana. Through its various subsidiaries, including Dr. Reddy’s Laboratories LLC in Russia, the company is engaged in the development, manufacture and sale of generic and branded medicines and related healthcare products across multiple international markets, with listings in India and on the New York Stock Exchange.
Average Trading Volume: 1,281,018
Technical Sentiment Signal: Hold
Current Market Cap: $11.26B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
